Beijing Science Sun Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Beijing Science Sun Pharmaceutical's earnings have been declining at an average annual rate of -2.5%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been declining at an average rate of 18.5% per year.
Key information
-2.5%
Earnings growth rate
-2.5%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | -18.5% |
| Return on equity | -2.9% |
| Net Margin | -19.5% |
| Next Earnings Update | 28 Aug 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Beijing Science Sun Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 453 | -89 | 291 | 60 |
| 31 Dec 23 | 477 | 103 | 291 | 78 |
| 30 Sep 23 | 529 | 149 | 297 | 75 |
| 30 Jun 23 | 623 | 222 | 350 | 94 |
| 31 Mar 23 | 675 | 99 | 380 | 111 |
| 01 Jan 23 | 735 | 205 | 429 | 101 |
| 30 Sep 22 | 841 | 517 | 521 | 103 |
| 30 Jun 22 | 912 | 551 | 570 | 97 |
| 31 Mar 22 | 1,010 | 466 | 630 | 99 |
| 01 Jan 22 | 1,051 | 402 | 658 | 104 |
| 30 Sep 21 | 1,112 | 163 | 690 | 109 |
| 30 Jun 21 | 1,132 | 155 | 719 | 103 |
| 31 Mar 21 | 1,160 | 172 | 741 | 82 |
| 31 Dec 20 | 1,094 | 155 | 710 | 72 |
| 30 Sep 20 | 1,103 | 151 | 713 | 75 |
| 30 Jun 20 | 1,140 | 140 | 773 | 66 |
| 31 Mar 20 | 1,163 | 129 | 809 | 59 |
| 31 Dec 19 | 1,191 | 149 | 820 | 50 |
| 30 Sep 19 | 1,367 | 200 | 951 | 18 |
| 30 Jun 19 | 1,390 | 245 | 913 | 20 |
| 31 Mar 19 | 1,352 | 268 | 866 | 24 |
| 31 Dec 18 | 1,428 | 283 | 896 | 32 |
| 30 Sep 18 | 1,206 | 292 | 692 | 30 |
| 30 Jun 18 | 1,059 | 308 | 528 | 38 |
| 31 Mar 18 | 912 | 296 | 389 | 28 |
| 31 Dec 17 | 750 | 282 | 266 | 16 |
| 30 Sep 17 | 631 | 257 | 172 | 18 |
| 30 Jun 17 | 576 | 232 | 158 | 0 |
| 31 Mar 17 | 588 | 245 | 148 | 0 |
| 31 Dec 16 | 616 | 258 | 158 | 0 |
| 30 Sep 16 | 620 | 255 | 145 | 0 |
| 30 Jun 16 | 620 | 236 | 154 | 0 |
| 31 Mar 16 | 612 | 222 | 149 | 0 |
| 31 Dec 15 | 607 | 209 | 145 | 0 |
| 30 Sep 15 | 606 | 204 | 143 | 0 |
| 30 Jun 15 | 607 | 208 | 140 | 0 |
| 31 Mar 15 | 605 | 205 | 168 | 0 |
| 31 Dec 14 | 590 | 203 | 138 | 0 |
| 31 Dec 13 | 480 | 161 | 107 | 0 |
Quality Earnings: 300485 is currently unprofitable.
Growing Profit Margin: 300485 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300485 is unprofitable, and losses have increased over the past 5 years at a rate of 2.5% per year.
Accelerating Growth: Unable to compare 300485's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300485 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: 300485 has a negative Return on Equity (-2.94%), as it is currently unprofitable.